# 1 High-throughput detection of neutralizing antibodies to

# 2 SARS-CoV-2 variants using flow cytometry

- 3
- 4 Running Head: High-throughput broad SARS-CoV-2 variants
- 5 neutralizing assay
- 6
- 7 Xiaohan Zhang<sup>1,2\*</sup>, Yajie Wang<sup>3\*</sup>, Mansheng Li<sup>1\*</sup>, Haolong Li<sup>4\*</sup>, Xiaomei
- <sup>8</sup> Zhang<sup>1</sup>, Xingming Xu<sup>1</sup>, Di Hu<sup>5</sup>, Te Liang<sup>1</sup>, Yunping Zhu<sup>1</sup>, Yongzhe Li<sup>4#</sup>,
- 9 Bingwei Wang<sup>2#</sup> and Xiaobo Yu<sup>1,6#</sup>
- 10

### 11 Affiliations

<sup>1</sup>State Key Laboratory of Medical Proteomics, Beijing Proteome
Research Center, National Center for Protein Sciences-Beijing
(PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206,
China.

<sup>16</sup> <sup>2</sup>School of Medicine, Nanjing University of Chinese Medicine, Nanjing

17 210023, China.

<sup>18</sup> <sup>3</sup>Department of Clinical Laboratory, Beijing Ditan Hospital, Capital

- 19 Medical University, Beijing 100015, China.
- <sup>4</sup>Department of Clinical Laboratory, Peking Union Medical College
- 21 Hospital, Chinese Academy of Medical Science & Peking Union
- 22 Medical College, Beijing 100730, China.

- <sup>23</sup> <sup>5</sup>ProteomicsEra Medical Co., Ltd., Beijing, 102206, China
- <sup>6</sup>The First Affiliated Hospital of Wenzhou Medical University, Wenzhou,
- 25 China.
- <sup>\*</sup>These authors contributed equally to this work.
- <sup>27</sup> <sup>#</sup>Correspondence to xiaobo.yu@hotmail.com (X.Y.),
- bingweiwang@njucm.edu.cn (B.W.) and yongzhelipumch@126.com (Y.
- 29 L).

- -

# 45 Abstract

46	Detecting neutralizing antibodies (NAbs) to SARS-CoV-2 variants is
47	crucial for controlling COVID-19 spread. We developed a
48	high-throughput assay for the broad systematic examination of NAbs to
49	eleven SARS-CoV-2 variants, which include D614G, Alpha, Beta,
50	Gamma, Delta, Kappa, and Omicron sub-lineages BA.1-BA.5. The
51	assay is cost-effective, reliable, 35-fold more sensitive than Luminex
52	technology, and can include new variants during SARS-CoV-2
53	evolution. Importantly, our results highly correlated with a commercial
54	IgG serological assay (R = 0.89) , the FDA-approved cPass sVNT
55	assay (R = 0.93), pseudivirus-based neutralizing assay (R = 0.96, R =
56	0.66, R = 0.65) and live virus based neutralization assay (R = 0.79, R =
57	0.64) . Using this platform, we constructed a comprehensive overview
58	of the interactions between SARS-CoV-2 variants' Spike trimer proteins
59	and ACE2 receptors, and identified a polyclonal Ab with broad
60	neutralizing activity. Furthermore, when compared to the D614G
61	variant, we found that the serum NAbs elicited by the third dose
62	vaccine demonstrated decreased inhibition to multiple SARS-CoV-2
63	variants, including Gamma (0.94×), Alpha (0.91×), Delta (0.91×), Beta
64	(0.81×), Kappa (0.81×), BA.2 (0.44×), BA.1 (0.43×), BA.3 (0.41×), BA.5
65	(0.35x) and BA.4 (0.33x), in cohort of 56 vaccinated individuals.
66	Altogether, our proteomics platform proves to be an effective tool to

- 67 detect broad NAbs in the population and aid in the development of
- <sup>68</sup> future COVID-19 vaccines and vaccination strategies.

# 69 Keywords

- 70 SARS-CoV-2, flow cytometry, neutralization, antibody, COVID-19

### 89 Introduction

The ongoing coronavirus 2019 (COVID-19) pandemic, caused by the 90 91 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 92 remains a public health concern worldwide. This is primarily attributed to the continuous evolution of the virus and its persistent transmission 93 across global populations<sup>1</sup>. For instance, over ten SARS-CoV-2 94 variants of concern (VOCs) have appeared, and these VOCs have the 95 potential to reduce the immune response<sup>2</sup>. According to reports, 17.13% 96 97 (95%CI, 7.55–26.71%) of asymptomatic infected individuals may have long-term health consequences<sup>3</sup>, which may include symptoms such 98 as fatigue, brain fog, dizziness, gastrointestinal symptoms, as well as 99 others<sup>4</sup>. 100

101 Neutralizing antibodies (NAbs) of SARS-CoV-2 are a subset of 102 antibodies that block viral entry by inhibiting the interaction between 103 the SARS-CoV-2's surface protein, Spike, and the host cell's receptor, angiotensin-converting enzyme 2 (ACE2). Such NAbs can be 104 105 produced following COVID-19 vaccination or SARS-CoV-2 infection. 106 Identifying SAR-CoV-2 NAbs is critical for assessing vaccine efficacy, 107 evaluating individual and population immunity, monitoring variant 108 susceptibility, and information public health measures to control the 109 spread of COVID-19. However, traditional methods of NAb detection, 110 such those that use a live virus or a pseudovirus-based neutralization

assay, are slow, expensive, carry a potential risk of infection, and may

require specialized biosafety level 3 (BSL3) facilities <sup>5-8</sup>.

113 As an alternative approach, enzyme-linked immunosorbent assay (ELISA) can perform the *in vitro* neutralizing testing using purified 114 115 Spike, ACE2, or Spike's receptor-binding domain (RBD) that interacts 116 directly with ACE2 during viral entry. Several commercial ELISA-based surrogate virus neutralization tests (sVNT) have been developed, 117 118 including TECO sVNT (TECO Medical) and cPASS sVNT (GenScript), 119 which have been approved by the United States' (U.S.) Food and Drug Administration (FDA) or received Conformite Europeenne (CE) 120 marking for use in the European Union <sup>9,10</sup>. Unfortunately, 121 122 ELISA-based methods only detect a single variant at a time, making 123 them a time-consuming option when multiple SARS-CoV-2 variants are analyzed <sup>6</sup>. 124

To address this concern, Fenwick et al. developed a multiplexed 125 in-vitro quantitative neutralization assay using Luminex technology in 126 127 2021. The assay enables the detection of NAbs targeting various Spike 128 mutations, including D614G, D614G plus M153T, N439K, S477N, 129 S477R, E484K, S459Y, N501T, N501Y, K417N, 60-70, P681H, Y453F, 130 and their combinations. The results obtained from this assay correlated with pseudovirus neutralization ( $R^2$ =0.65) and live virus infection ( $R^2$ = 131 0.825) assays <sup>(</sup>. 132

In a similar vein, Lynch et al. developed a multiplexed surrogate
virus neutralization test (plex-sVNT) for detecting NAbs to seven
SARS-CoV-2 variants, namely, wild type, Alpha, Beta, Gamma, Delta,
Kappa, and Epsilon. The results highly correlated (> 96%) with those
obtained from a plaque reduction neutralization test (PRNT)<sup>8</sup>.

However, it should be noted that these technologies have limitations as they require access to specific Luminex and Bio-Rad instruments, thereby restricting their use to specific laboratories. Moreover, some recent Omicron variants have not been accessible for analysis using these methods to date<sup>11</sup>.

143 In this work, we developed a high-throughput broad neutralizing 144 antibody (bNAb) assay that enables the systematic detection of NAbs to eleven SARS-CoV-2 VOCs that is reliable, cost-effective, sensitive, 145 and used with a standard flow cytometer <sup>12</sup>. These variants include 146 147 D614G, Alpha, Beta, Gamma, Delta, Kappa, Omicron BA.1, Omicron 148 BA.2, Omicron BA.3, Omicron BA.4, and Omicron BA.5. We conducted 149 a comparative analysis of NAb detection using our SARS-CoV-2 bNAb 150 assay with commercial ELISA-based serology, U.S. FDA-approved 151 cPASS sVNT, pseudivirus-based neutralizing assays and live virus 152 based neutralization assay. Furthermore, we explored the applications 153 of the SARS-CoV-2 bNAb assay for screening therapeutic Abs, 154 assessing their neutralizing activity SARS-CoV-2. Finally, we analyzed

the broad responses of serological NAbs to SARS-CoV-2 variants in
individuals who received the third dose of either the inactivated vaccine
(Sinovac-CoronaVac) or the recombinant subunit vaccine (ZF2001) for

158 COVID-19.

159

160 **Results** 

#### 161 Schematic illustration of SARS-CoV-2 bNAb assay

162 In the SARS-COV-2 bNAb assay, illustrated schematically in Figure 1A, 163 the trimerized Spike proteins of six non-Omicron variants (D614G, 164 Alpha, Beta, Kappa, Gamma, Delta) and five Omicron variants (BA.1, 165 BA.2, BA.3, BA.4, BA.5) were expressed from human embryonic 166 kidney 293 (HEK293) cells, purified, and coupled to the magnetic-fluorescent beads, as previously reported <sup>7,13</sup>. During the 167 168 NAbs detection process, all coupled beads were mixed together and 169 incubated with samples containing NAbs. The NAbs bound to the 170 Spike trimer proteins, preventing their interaction with the biotinylated 171 ACE2 receptors, which were coupled to streptavidin-phycoerythrin 172 (SA-PE). The inhibition rate (%) was calculated as follows: Inhibition 173 rate (%) = (1 - signal of NAb inhibition on Spike-ACE2 binding / signal174 of Spike-ACE2 binding) × 100%.

The sensitive detection of Spike-ACE2 interactions is essential for assessing the presence of NAbs in clinical samples. To address this

177 requirement, we coupled the Spike protein from six SARS-CoV-2 variants (D614G, Alpha, Beta, Kappa, Delta, Omicron BA.1) onto 178 179 magnetic-fluorescent beads from Luminex and Shenzhen Wellgrow Technology Co., Ltd. ("Wellgrow"), and then incubated with different 180 181 concentrations of ACE2. Magnetic-fluorescent beads with the SARS-CoV-2 nucleocapsid (N) protein, rather than the Spike protein, 182 183 was employed as the negative control. The binding signals were 184 measured using Luminex-200 and Wellgrow flow cytometry. Notably, 185 the fluorescent signal intensity and signal to noise ratio (SNR) were 186 much higher with the Wellgrow platform than the Luminex platform when ACE2 concentrations ranged from 0.01 µg/mL to 100 µg/mL 187 188 (Figure 1B, Figure S1 and Table S6).

Furthermore, we calculated the sensitivity or the lowest detection limit (LOD) of each method, in which the LOD was equal to the signal of the buffer control plus ten standard deviations (Figure 1C). The data showed that the average LOD of our assay using the Wellgrow platform was 35.89±57.8 [-21.91~93.69]-fold higher than the Luminex platform for all variants (D614G, Alpha, Beta, Kappa, Delta, Omicron BA.1).

At last, we compared the difference of NAb titers obtained by detecting the inhibition of antibody #26 to Spike-ACE2 interaction. The results showed that the IC50 obtained by two platforms are highly

consistence with the r correlation of 0.9988 (Figure S1D). Therefore,

we chose the Wellgrow platform as the proteomics platform for the

- 201 SARS-CoV-2 bNAb assay in this study.
- 202

#### 203 Mapping Spike-ACE2 interactions of SARS-CoV-2 variants

Using our platform, we conducted a systematic investigation of the interactions between ACE2 and Spike trimer proteins from eleven SARS-CoV-2 variants. This was achieved by incubating a bead array with different concentrations of ACE2 (Figure 2). The results demonstrated that the fluorescent signals from the Spike trimer proteins increased with increasing concentrations of ACE2, indicating the formation of Spike-ACE2 complexes on the beads (Figure 2A).

Spike mutations were found to influence the interaction dynamics. At the maximal concentration of 10  $\mu$ g/mL ACE2, Alpha and Delta variants exhibited the highest signals, followed by Beta, BA.4, BA.5, D614G, Gamma, BA.1, BA.2, and Kappa, with BA.3 showing the lowest signal. In contrast, the N protein, used as a negative control, consistently displayed the lowest signal regardless of ACE2 concentration.

To further assess the binding affinity, we calculated the half-maximal effective concentration (EC50) using the standard curve for each SARS-CoV-2 variant (Figure 2B). The results showed that

221	Omicron BA.1 has the highest binding affinity with an EC50 of 0.2913
222	$\mu$ g/mL, followed by Beta (0.2913 $\mu$ g/mL), Delta (0.3415 $\mu$ g/mL),
223	Omicron BA.4 (0.3592 µg/mL), Gamma (0.3833 µg/mL), Alpha (0.394
224	μg/mL), Kappa (0.3983 μg/mL), Omicron BA. 2 (0.4307μg/mL),
225	Omicron BA. 5(0.4593 µg/mL), D614G (0.5279 µg/mL), and Omicron
226	BA.3 (1.283 $\mu$ g/mL). The results are in accordance with surface plasma
227	resonance data in which BA.1 has the strongest interaction with ACE2
228	with a dissociation constant ( $K_D$ ) of 2.10 nM, followed by BA.2 (2.21 nM)
229	and D614G (5.20 nM) <sup>14</sup> . Similar results were obtained by Mahalingam
230	et al., who used ELISA to determine the EC50 of ACE2 to Spike
231	Omicron (0.38 nM), Delta (0.48 nM), and wild type $(2.28 \text{ nM})^{15}$ .
232	Collectively, our data provide a comprehensive landscape of Spike
233	trimer-ACE2 interactions for SARS-CoV-2 VOCs, as classified by the
234	U.S. Centers for Disease Control and Prevention (CDC)
235	(https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifica
236	tions.html). It should be noted that the Epsilon variant was not included
237	in this work due to the unavailability of purified Spike trimer protein at
238	the time of executing experiments.

In addition, to demonstrate the specificity of our assay, we tested
the binding ability of ACE2 to the Spike proteins from MERS,
SARS-CoV and six SARS-CoV-2 variants. The results showed that the
binding signal of ACE2 to six SARS-CoV-2 variant Spike proteins was

243	much higher than that of SARS-CoV and MERS. The binding signal of
244	SARS-CoV was 3.38-5.74 times lower than that of SARS-CoV-2
245	variants, due to the homology of Spike sequence. There was no
246	binding signal observed between ACE2 and MERS, similar to the
247	negative control, N protein (Figure S2). All these results are accord to
248	the reported results <sup>16</sup> , and demonstrate our assay is specific.

249

# 250 Comparison of SARS-CoV-2 bNAb assay to ELISA , cPass sVNT,

# 251 pseudovirus-based neutralization and live virus based 252 neutralization assays.

To assess the reliability of the SARS-CoV-2 bNAb assay, we compared the SARS-CoV-2 bNAb assay to an ELISA that was used to detect anti-Spike IgG antibodies<sup>17</sup>. The results showed a high correlation between the levels of D614G NAbs detected using our SARS-CoV-2 bNAb assay and the anti-Spike IgG antibodies obtained by the ELISA [R = 0.89, p-value (p) < 2.2 e-16] in a cohort of 75 individuals (Figure 3A).

Next, we compared the NAb results obtained from the SARS-CoV-2 bNAb assay to those obtained from the FDA-approved cPass sVNT test <sup>6,9</sup>. The data obtained using the SARS-CoV-2 bNAb assay and cPass sVNT test demonstrated a higher correlation to each other (R = 0.93, p < 2.2 e-16) compared to the assay using Luminex

265	technology (R = $0.85$ ) <sup>18</sup> . The positive percent agreement (PPA) was
266	92.7% (80.1%-98.5%) and the negative percent agreement (NPA) was
267	94.1% (80.3%-99.3%) (Figure 3B). The findings suggest that some of
268	the anti-Spike IgG antibodies detected by the ELISA may lack
269	neutralizing activity and therefore were not detected by SARS-CoV-2
270	bNAb assay <sup>19</sup> . Overall, these results demonstrate the reliability of the
271	SARS-CoV-2 bNAb assay as an in vitro platform for detecting serum
272	NAbs.

273 Additionally, we compared the inhibition rate (%) of NAbs obtained by SARS-CoV-2 bNAb assay to the NAb titers obtained by 274 live virus 275 pseudovirus-based neutralization assay or based 276 neutralization assay. For 10 serum samples from mice administered with WT mRNA vaccines, a high correlation was found between D614G 277 278 NAbs inhibition rate (%) detected using SARS-CoV-2 bNAb assay and 279 WT NAb titers by pseudovirus-based neutralization assay (R = 0.96, p 280 < 0.0001) and live virus based neutralization assay (R = 0.79, p <0.0001) (Figures 3C, 3E). Similarly, for 10 serum samples from mice 281 282 administered with BA.1 mRNA vaccines, notable correlations were 283 observed between the levels of BA.1 NAbs detected using 284 SARS-CoV-2 bNAb assay and pseudovirus-based neutralization (R = 285 0.66, p = 0.0017) and live virus based neutralization assays (R = 0.64, p = 0.0022) (Figures 3D, 3F). Then, we compared the inhibition rate (%) 286

of NAbs obtained by SARS-CoV-2 bNAb assay and the NAb titers obtained by pseudovirus-based neutralization assay in the serum of 135 individuals with second dose vaccination. We detected serum NAbs against the D614G variant using both assays. The results showed a correlation coefficient (r) of 0.65, demonstrating the consistency between the results obtained through inhibition and those obtained with NAb titers (Figure S4 and Table S7).

294

#### 295 Identification of broadly neutralizing monoclonal/polyclonal Abs

#### against SARS-CoV-2 variants

To demonstrate the application of SARS-CoV-2 bNAb assay in 297 298 identifying monoclonal/polyclonal NAbs for potential treatment 299 purposes, we tested six anti-Spike antibodies that are available in the laboratory<sup>20</sup> (Figure 4A). The results revealed that three antibodies 300 301 (#26, #20, #21) have neutralizing activity. Antibodies #20 and #21 inhibited ACE2 binding to D614G, Alpha, Beta, Kappa and Delta 302 303 variants, but were not effective in inhibiting the ACE2 binding to the 304 Omicron BA.1 variant. Antibody #26 exhibited the ability to inhibit 305 Spike-ACE2 interactions for D614G, Alpha, Beta, Kappa, Delta and 306 Omicron BA.1 variants.

Subsequently, the half-maximal inhibitory concentration (IC50)
 values were calculated and represented in a heatmap (Figure 4B). The

309	results showed that antibody #26 possessed broad neutralizing activity
310	to all tested SARS-CoV-2 variants (Kappa, D614G, Alpha, Delta, Beta,
311	Omicron BA.1). The IC50 to D614G (0.47 $\mu\text{g/mL})$ was confirmed with
312	ELISA (0.35 $\mu\text{g/mL})$ and pseudovirus neutralizing assay (0.21 $\mu\text{g/mL})$
313	in our previous work <sup>20</sup> . While the IC50 of antibody #26 to the Omicron
314	variant was ten-fold lower than non-Omicron variants. These findings
315	underscore the ability of our assay to rapidly screen for
316	monoclonal/polyclonal NAbs with potential therapeutic applications.
317	
318	Evaluation of serum NAbs in individuals receiving the third dose
319	vaccination
320	We tested the serum NAbs from 56 individuals who received two doses
321	
	of the inactivated vaccine (Sinovac-CoronaVac) and boosted with a
322	of the inactivated vaccine (Sinovac-CoronaVac) and boosted with a third dose with either an inactivated vaccine or recombinant subunit
322 323	
	third dose with either an inactivated vaccine or recombinant subunit
323	third dose with either an inactivated vaccine or recombinant subunit vaccine (ZF2001) (Table 1) <sup>21</sup> . The inhibition rate (%) was calculated by
323 324	third dose with either an inactivated vaccine or recombinant subunit vaccine (ZF2001) (Table 1) <sup>21</sup> . The inhibition rate (%) was calculated by deducting the background noise using 147 serum samples collected
323 324 325	third dose with either an inactivated vaccine or recombinant subunit vaccine (ZF2001) (Table 1) <sup>21</sup> . The inhibition rate (%) was calculated by deducting the background noise using 147 serum samples collected prior to the COVID-19 pandemic <sup>22</sup> . The results showed that the third
323 324 325 326	third dose with either an inactivated vaccine or recombinant subunit vaccine (ZF2001) (Table 1) <sup>21</sup> . The inhibition rate (%) was calculated by deducting the background noise using 147 serum samples collected prior to the COVID-19 pandemic <sup>22</sup> . The results showed that the third dose vaccination elicited a strong protective immune response against
323 324 325 326 327	third dose with either an inactivated vaccine or recombinant subunit vaccine (ZF2001) (Table 1) <sup>21</sup> . The inhibition rate (%) was calculated by deducting the background noise using 147 serum samples collected prior to the COVID-19 pandemic <sup>22</sup> . The results showed that the third dose vaccination elicited a strong protective immune response against the non-Omicron variants with the highest inhibition rate (%) of D614G,

indicating the resistance of these variants to the Sinovac-CoronaVac

vaccine and the ZF2001 vaccine (Figure 5A).

333	Next, we compared the inhibition (%) of serum NAbs in individuals
334	who received either a third dose of inactivated vaccine or recombinant
335	vaccine; no significant difference was observed (Figure 5B). These
336	findings highlight the immunological resistance of different
337	SARS-CoV-2 variants to the Sinovac-CoronaVac and ZF2001 vaccines,
338	and suggest the need for developing a new vaccine that provides
339	broad protection against SARS-CoV-2 variants.
340	Furthermore in order to demonstrate the specificity of our
341	SARS-CoV-2 bNAb assay, we detected the serum from the individuals
342	before vaccination ( $n = 147$ ) and after three-dose vaccination ( $n = 56$ ).

The results showed that the serum NAb levels were significantly higher in the vaccination group than un-vaccination group (p < 0.0001) (Figure S3), indicating our SARS-CoV-2 bNAb assay is highly specific for the

347

346

#### 348 **Discussion**

detection of serum NAbs.

Even though the World Health Organization has announced that COVID-19 is no longer a public health emergency of international concern, the genome sequence of SARS-CoV-2 is continually evolving and the new variants (i.e. EG.5) may has the potential to escape the

immunity and threat the people's health, especially among
immunocompromised individuals<sup>23,24</sup>. Therefore, there is still a need for
effective COVID-19 vaccines to prevent and control viral transmission.
The development and deployment of vaccines for COVID-19, as well
as the evaluation of population immunity, remain important for public
health<sup>25</sup>.

In this work, we developed a high-throughput SARS-CoV-2 bNAb 359 360 assay to detect a wide range of NAbs to non-Omicron and Omicron variants. Compared to the assay using Luminex technology<sup>7,8</sup>, our 361 362 SARS-CoV-2 bNAb assay is 35-fold more sensitive, 2.5-fold less costly, 363 and can be accessible to any laboratory that has a standard flow 364 cytometer with the 532 nm and 635 nm lasers. Moreover, the simultaneous detection of NAbs to multiple SARS-CoV-2 variants can 365 be achieved within a single experiment, and the assay can be 366 periodically updated to include new variants. The reliability of NAb 367 detection using our SARS-CoV-2 bNAb assay is demonstrated through 368 369 comparisons with ELISA-based IgG serology, the cPass sVNT assay, 370 pseudovirus-based neutralization assay and live virus based 371 neutralization assay (Figure 3).

Using this platform, we constructed a comprehensive landscape of Spike trimer and ACE2 interactions for eleven SARS-CoV-2 variants (Figure 2). The results provide evidence that Omicron BA.1 showed the

strongest binding affinity to the ACE2 receptor  $^{26,27}$ . Notably, the transmission rate of SARS-CoV-2 and its variants is dependent on numerous factors, including immune resistance, toxicity, etc<sup>28</sup>.

378 Furthermore, our investigation of serum NAbs in vaccinated 379 individuals showed that the third dose of the inactivated vaccine or recombinant RBD vaccine resulted in a strong inhibition of Spike-ACE2 380 381 interactions to the non-Omicron variants (D614G, Alpha, Beta, Gamma, 382 Kappa). However, the protection was significantly decreased for 383 Omicron variants (BA.2, BA.1, BA.3, BA.5, BA.4) (Figure 5). These 384 results demonstrate the significance of our proteomics platform in 385 evaluating the broad protective activity of COVID-19 vaccines, which 386 can guide the development of COVID-19 vaccines.

387 It is important to acknowledge some limitations of our study. First, 388 the *in vitro* detection of NAbs may not represent viral neutralization *in* vivo, although previously reported evidence has shown a good 389 correlation between NAbs detected in vitro and vivo5-8. Second, the 390 391 relationship between the inhibition levels obtained with the 392 SARS-CoV-2 bNAb assay and the SARS-CoV-2 infection remains 393 unclear. Third, the number of clinical samples employed in this study 394 was limited, and the assay should be executed in a larger cohort to 395 determine the NAb levels induced by different vaccines and infection with SARS-CoV-2 variants. Finally, the SARS-CoV-2 wild-type was not 396

397	employed due to the unavailability of this protein during executing
398	experiments. Instead, we employed the D614G variant, which shares
399	high homology with the wild type. Previous studies have demonstrated
400	comparable neutralization potency between the D614G variant and the
401	wild type <sup>29</sup> . Additionally, the D614G substitution does not significantly
402	alter SARS-CoV-2 morphology and binding to the ACE2 receptor <sup>30</sup> .

403

## 404 **Conclusion**

405 We have successfully developed and validated a high-throughput proteomics platform, enabling the comprehensive evaluation of NAbs 406 against a wide range of SARS-CoV-2 variants. This platform offers an 407 408 efficient, sensitive, and cost-effective approach for detecting broad NAbs within the population, providing an opportunity to guide the 409 410 design and evaluation of vaccines with enhanced protective efficacy 411 against evolving SARS-CoV-2 strains. Overall, our work contributes to 412 the ongoing efforts in combating the COVID-19 pandemic and advancing our understanding of immune responses to SARS-CoV-2. 413

414

### 415 **References**

The L. The COVID-19 pandemic in 2023: far from over. Lancet. 2023;401(10371):79.
 Khoury DS, Docken SS, Subbarao K, et al. Predicting the efficacy of variant-modified
 COVID-19 vaccine boosters. Nat Med. 2023;29(3):574-578.
 Ma Y, Deng J, Liu Q, et al. Long-Term Consequences of Asymptomatic SARS-CoV-2
 Infection: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health.
 2023;20(2).

422	4.	Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute
423		Sequelae of SARS-CoV-2 Infection. JAMA. 2023.
424	5.	Nie J, Li Q, Wu J, et al. Quantification of SARS-CoV-2 neutralizing antibody by a
425		pseudotyped virus-based assay. <i>Nat Protoc</i> . 2020;15(11):3699-3715.
426	6.	Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test
427		based on antibody-mediated blockage of ACE2-spike protein-protein interaction.
428		Nat Biotechnol. 2020;38(9):1073-1078.
429	7.	Fenwick C, Turelli P, Pellaton C, et al. A high-throughput cell- and virus-free assay
430		shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent
431		plasma. <i>Sci Transl Med</i> . 2021;13(605).
432	8.	Lynch KL, Zhou S, Kaul R, et al. Evaluation of Neutralizing Antibodies against
433		SARS-CoV-2 Variants after Infection and Vaccination Using a Multiplexed Surrogate
434		Virus Neutralization Test. Clin Chem. 2022;68(5):702-712.
435	9.	Perkmann T, Mucher P, Osze D, et al. Comparison of five Anti-SARS-CoV-2 antibody
436		assays across three doses of BNT162b2 reveals insufficient standardization of
437		SARS-CoV-2 serology. <i>J Clin Virol</i> . 2023;158:105345.
438	10.	Bal A, Pozzetto B, Trabaud MA, et al. Evaluation of High-Throughput SARS-CoV-2
439		Serological Assays in a Longitudinal Cohort of Patients with Mild COVID-19: Clinical
440		Sensitivity, Specificity, and Association with Virus Neutralization Test. Clin Chem.
441		2021;67(5):742-752.
442	11.	Grant R, Sacks J, Abraham P, et al. When to update COVID-19 vaccine composition.
443		Nature Medicine 2023(29):776–780.
444	12.	Chao Z, Han Y, Jiao Z, et al. Prism Design for Spectral Flow Cytometry.
445		Micromachines (Basel). 2023;14(2).
446	13.	Yu X, Hartmann M, Wang Q, et al. microFBI: a microfluidic bead-based
447		immunoassay for multiplexed detection of proteins from a microL sample volume.
448		PLoS One. 2010;5(10).
449	14.	Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron
450		subvariants BA.2.12.1, BA.4 and BA.5. <i>Nature.</i> 2022;608(7923):603-608.
451	15.	Mahalingam G, Arjunan P, Periyasami Y, et al. Correlating the differences in the
452		receptor binding domain of SARS-CoV-2 spike variants on their interactions with
453		human ACE2 receptor. <i>Sci Rep.</i> 2023;13(1):8743.
454	16.	Gorbalenya AE, Baker SC, Baric RS, et al. The species Severe acute respiratory
455		syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2.
456		Nature Microbiology. 2020;5(4):536-544.
457	17.	Zhan H, Gao H, Liu Y, et al. Booster shot of inactivated SARS-CoV-2 vaccine induces
458		potent immune responses in people living with HIV. J Med Virol.
459		2023;95(1):e28428.
460	18.	Marien J, Michiels J, Heyndrickx L, et al. Evaluation of a surrogate virus
461		neutralization test for high-throughput serosurveillance of SARS-CoV-2. J Virol
462		Methods. 2021;297:114228.
463	19.	Chen Y, Zhao X, Zhou H, et al. Broadly neutralizing antibodies to SARS-CoV-2 and
464		other human coronaviruses. <i>Nat Rev Immunol.</i> 2023;23(3):189-199.
465	20.	Liang T, Cheng M, Teng F, et al. Proteome-wide epitope mapping identifies a
		C , many my many many many many many many m

466		resource of antibodies for SARS-CoV-2 detection and neutralization. <i>Signal</i>			
467		Transduct Target Ther. 2021;6(1):166.			
468	21.	Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 Neutralization from Inactivated			
469		and ZF2001 Vaccines. N Engl J Med. 2022;387(3):277-280.			
470	22.	Zhang J, Teng F, Zhang X, et al. Down-regulation of SARS-CoV-2 neutralizing			
471		antibodies in vaccinated smokers. <i>MedComm (2020)</i> . 2022;3(3):e166.			
472	23.	Faraone JN, Qu P, Goodarzi N, et al. Immune evasion and membrane fusion of			
473		SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3. Emerging Microbes & Infections.			
474		2023;12(2).			
475	24.	Antinori A, Bausch-Jurken M. The Burden of COVID-19 in the Immunocompromised			
476		Patient: Implications for Vaccination and Needs for the Future. The Journal of			
477		Infectious Diseases. 2023;228(Supplement_1):S4-S12.			
478	25.	Lotfi H, Mazar MG, Ei NMH, et al. Vaccination is the most effective and best way to			
479		avoid the disease of COVID-19. Immunity, Inflammation and Disease. 2023;11(8).			
480	26.	Yin W, Xu Y, Xu P, et al. Structures of the Omicron spike trimer with ACE2 and an			
481		anti-Omicron antibody. <i>Science</i> . 2022;375(6584):1048-1053.			
482	27.	Ma W, Fu H, Jian F, et al. Immune evasion and ACE2 binding affinity contribute to			
483		SARS-CoV-2 evolution. <i>Nat Ecol Evol</i> . 2023.			
484	28.	Markov PV, Katzourakis A, Stilianakis NI. Antigenic evolution will lead to new			
485		SARS-CoV-2 variants with unpredictable severity. <i>Nat Rev Microbiol.</i>			
486		2022;20(5):251-252.			
487	29.	Yurkovetskiy L, Wang X, Pascal KE, et al. Structural and Functional Analysis of the			
488		D614G SARS-CoV-2 Spike Protein Variant. <i>Cell.</i> 2020;183(3):739-751 e738.			
489	30.	Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient			
490		replication ex vivo and transmission in vivo. <i>Science</i> . 2020;370(6523):1464-1468.			
491	31.	Zhang X, Zheng M, Wang H, et al. Inhibitor screening using microarray identifies the			
492		high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection			
493		and vaccination. <i>Theranostics</i> . 2022;12(6):2519-2534.			
494	32.	Yang L, Yu Y, Ma C, et al. Development of RBC Membrane Antigen Arrays for			
495		Validating Blood Grouping Reagents. <i>J Proteome Res</i> . 2018;17(9):3237-3245.			
496	33.	Salazar-García M, Acosta-Contreras S, Rodríguez-Martínez G, et al. Pseudotyped			
497		Vesicular Stomatitis Virus-Severe Acute Respiratory Syndrome-Coronavirus-2 Spike			
498		for the Study of Variants, Vaccines, and Therapeutics Against Coronavirus Disease			
499		2019. Frontiers in Microbiology. 2022;12.			
500	34.	Nie J, Li Q, Wu J, et al. Establishment and validation of a pseudovirus neutralization			
501		assay for SARS-CoV-2. Emerging Microbes & Infections. 2020;9(1):680-686.			
502	35.	Chen G-L, Li X-F, Dai X-H, et al. Safety and immunogenicity of the SARS-CoV-2			
503		ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind,			
504		placebo-controlled, phase 1 trial. <i>The Lancet Microbe</i> . 2022;3(3):e193-e202.			
505	36.	Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to			
506		analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.			
507					

# 508 **Contributions**

509	X.Z. and D.H. executed the experiments; M.L., X. Z., X.Z., X.X., T. L.,
510	and Y. Z. performed the data analysis; H.L. and Y.W. provided the
511	clinical samples. X.Y., Y. L., B.W. and X.Z. wrote and revised the paper.
512	

### 513 Acknowledgment

This work was supported by the Beijing Municipal Natural Science 514 Foundation (M23010 and L234034), National Key R&D Program of 515 516 China(2022YFE0210400, 2021YFA1301604, 2020YFE0202200), State Key Laboratory of Proteomics (SKLP-O202007), Academic 517 518 leader of high-level public health technical personnel construction 519 project of Beijing Municipal Health Commission (2022-2-014), 520 Guangdong Province Science and Technology Planning Project 521 (2020B1111100006), Innovation Team and Talents Cultivation Program 522 of National Administration of Traditional Chinese Medicine. (No: 523 ZYYCXTD-C-202204). We would like to thank the bioinformatics platform of the National Center for Protein Sciences (Beijing) for their 524 525 support in the data analysis of this project. We also thank Dr. Brianne 526 Petritis for her critical review and editing of this manuscript.

527

# 528 **Declaration of Interest Statement**

529 The authors have declared no conflict of interest.

### 530

# 531 Supplementary materials

- 532 This article contains Supplementary Figure 1-4 and Supplementary
- 533 Table1-7.
- 534

# 535 Tables

#### Table 1. Clinical serum samples employed in this study

	3 <sup>rd</sup> dose vaccination cohort
	( n=56 )
Gender	
Male	16(28.6%)
Female	40(71.4%)
Age (years)	
Range	21-70
≤50	50(89.3%)
>50	6(10.7%)
Vaccination type	
Recombinant RBD-subunit vaccine (ZF2001)	38(83.9%)
Inactivated vaccine (Sinovac-Coron aVac)	18(16.1%)
Days of serum collection after 3rd dose vaccination	28

537

# 538 Figure legends

539	Figure 1. Schematic illustration of the high throughput
540	SARS-CoV-2 bNAb assay. (A) Workflow of the SARS-CoV-2 bNAb
541	assay. The Spike-ACE2 interaction is a direct binding reaction between
542	Spike trimer proteins and biotinylated ACE2. Upon the addition of the

543 NAbs, the beads coupled with SARS-CoV-2 variants Spike trimer 544 proteins are incubated with NAbs. The NAbs with neutralizing activity 545 will block the Spike interaction with biotinylated ACE2 and SA-PE. The 546 signal intensities of the Spike trimer-ACE2 interaction are inversely 547 proportional to the level of NAbs. During the NAbs detection process, all coupled beads were mixed together and incubated with samples 548 549 containing NAbs. The NAbs bound to the Spike trimer proteins, 550 preventing their interaction with the biotinylated ACE2 receptors, which 551 were coupled to streptavidin-phycoerythrin (SA-PE). (B) Dose relationship curve of Spike-ACE2 interactions using Wellgrow and 552 553 Luminex platforms. MFI = mean fluorescence intensity. (C) A 554 comparison of the sensitivity to detect Spike-ACE2 interactions with the 555 Wellgrow and Luminex platforms.

556

Figure 2. Spike trimer-ACE2 interactions across different 557 558 SARS-CoV-2 variants and ACE2 concentrations. (A) Dose 559 relationship curve of the interactions between ACE2 and six 560 SARS-CoV-2 non-Omicron variants and five Omicron variants The 561 x-axis represents the concentrations of the host ACE2 receptor. The 562 y-axis represents the median of fluorescent signal intensity (MFI) of the 563 SARS-CoV-2 Spike trimer-ACE2 interaction. N = nucleocapsid protein, which was used as a negative control. (B) Distribution of the NAb 564

565	resistance to SARS-CoV-2 variants. The x-axis represents the
566	SARS-CoV-2 variants. The y-axis represents the EC50 calculated from
567	SARS-CoV-2 variant Spike-ACE2 interactions. The corresponding
568	values on the Y-axis are Omicron BA.1 (0.2913 $\mu\text{g/mL}),$ Beta (0.2913
569	μg/mL), Delta (0.3415 μg/mL), Omicron BA.4 (0.3592 μg/mL), Gamma
570	(0.3833 μg/mL), Alpha (0.394 μg/mL), Kappa (0.3983 μg/mL), Omicron
571	BA. 2 (0.4307μg/mL), Omicron BA. 5(0.4593 μg/mL), D614G (0.5279
572	μg/mL), and Omicron BA.3 (1.283 μg/mL), respectively.
573	
574	Figure 3. Comparison of SARS-CoV-2 bNAb assay to ELISA ,

cPass sVNT, pseudovirus-based neutralization and live virus 575 based neutralization assays. (A) Correlation analysis of serological 576 IgG detection between the SARS-CoV-2 bNAb assay and an 577 578 ELISA-based IgG serology. (B) Correlation analysis of NAb detection 579 using the SARS-CoV-2 bNAb assay and the FDA-approved cPass 580 sVNT test. The concordance of NAb detection using the ELISA and sVNT assays was calculated as the positive and negative percent 581 582 agreement (PPA and NPA, respectively). The blue and red dots 583 represent positive (neutralizing activity) and negative (non-neutralizing) cases as determined by the comparative analysis, respectively. (C) 584 585 Correlation analysis of D614G NAbs inhibition rate (%) from the SARS-CoV-2 bNAb assay with WT NAb titers from pseudovirus-based 586

587	neutralization assays. (D) Correlation analysis of BA.1 NAbs inhibition
588	rate (%) from the SARS-CoV-2 bNAb assay with BA.1 NAb titers from
589	pseudovirus-based neutralization assays. (E) Correlation analysis of
590	D614G NAbs inhibition rate (%) from the SARS-CoV-2 bNAb assay
591	with WT NAb titers from live virus based neutralization assays. (F)
592	Correlation analysis of BA.1 NAbs inhibition rate (%) from the
593	SARS-CoV-2 bNAb assay with BA.1 NAb titers from live virus based
594	neutralization assays.

595

Figure 4. Identification of monoclonal/polyclonal Abs with broad 596 597 **neutralizing capability.** (A) Dose relationship curve demonstrating the 598 ability of the NAb to inhibit SARS-CoV-2 variant Spike trimer-ACE2 599 interactions. The x-axis represents the concentrations of the NAb. The 600 y-axis represents the percent activity (%) of the NAb. N = nucleocapsid 601 protein, which was used as a negative control. (B) Heatmap showing 602 the IC50 of NAbs against different SARS-CoV-2 variants. The detail of 603 monoclonal/polyclonal Abs are provided in Table S5.

604

Figure 5. Detection of serum NAbs in vaccinated individuals. (A) Boxplot showing the distribution of inhibition rate (%) of serum NAbs against SARS-CoV-2 variants in 56 vaccinated individuals. (B) Comparison of NAbs produced between groups receiving the

609	inactivated vaccine (Sinovac-CoronaVac) or recombinant subunit							
610	vaccine (ZF2001). The significance was performed using the Student's							
611	<i>t</i> -test (p-value < 0.01). **, ***, and **** represent a p-value less than							
612	0.01, 0.001, and 0.0001, respectively.							
613								
614	Materials and methods							
615	Collection of clinical samples							
616								
010	Clinical serum samples were collected from Beijing Ditan Hospital 28							
617	Clinical serum samples were collected from Beijing Ditan Hospital 28 days after the third dose of the COVID-19 vaccine (Table 1). Whole							
617	days after the third dose of the COVID-19 vaccine (Table 1). Whole							
617 618	days after the third dose of the COVID-19 vaccine (Table 1). Whole blood was collected in a vacutainer tube, and the serum was obtained							

Hospital (No.2021-010-01), and an exemption of informed consent was

obtained before sera collection<sup>31</sup>.

624

### 625 **Preparation of SARS-CoV-2 bNAb reagents**

The SARS-CoV-2 bNAb assay was developed in ProteomicsEra Medical Co., Ltd (Beijing, China). Briefly, 3  $\mu$ g SARS-CoV-2 Spike trimer proteins (Sino Biological., Novoprotein and ACROBiosystems; China) (Table S1) were coupled to 1×10<sup>6</sup> magnetic-fluorescent beads (Wellgrow Technology Co., Ltd.) as previously described<sup>32</sup>. First, 12

differently encoded magnetic-fluorescent beads, numbered 102-108 631 632 and 201-205 (Table S2), were chosen. Then 125 µL containing 1×10<sup>6</sup> beads were washed with 100 µL ddH2O and activated with 80 633 µL of "activation buffer" (50 mM 2-(N-morpholino) ethanesulfonic acid 634 635 (MES) pH 5.0) (Sigma-Aldrich, St. Louis, MO). Then the activated 636 beads were mixed with 10 µL of 50 mg/mL sulfo-N-hydroxysuccinimide (NHS) (Thermo Scientific, USA) and 10 µL of 50 mg/mL 637 638 1-Ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC) 639 (Solarbio, Beijing, China). After incubation for 20 min at room 640 temperature with gentle mixing, the beads were washed twice with 250 641 µL "coupling buffer" (50 mM MES pH 5.0) and resuspended in 200 µL 642 coupling buffer. Then 3 µg of Spike trimer proteins were added to the 643 bead solution and incubated for 2 h at room temperature. After washing, 644 the beads underwent blocking with "blocking buffer" (PBST-B, PBS pH 645 7.4, 0.05% Tween-20, 1% BSA), and the coupled beads were subsequently stored at 2-8 °C in "storage buffer" (PBST-BN, PBS pH 646 7.4, 0.05% Tween-20, 0.1% BSA, 0.05% NaN3). 647

648

Detection of Spike-ACE2 interactions using SARS-CoV-2 bNAb
assay
First, a 50 µL mixed solution containing 12 different SARS-CoV-2 Spike

trimer protein-coupled beads (2500 beads per type) (Table S3) was

653	added to each well of a 96-well plate, followed by 50 $\mu L$ of different
654	concentrations (0, 0.014, 0.041, 0.123, 0.370, 1.111, 3.333, 10 µg/mL)
655	of biotinylated ACE2 (Sino Biological). After incubation for 1 h at room
656	temperature on a shaker, the beads were magnetically separated using
657	a magnetic separator (Wellgrow Technology Co., Ltd.) and washed
658	three times with 100 $\mu L$ PBST-B (PBS pH7.4 , 0.05% Tween-20, 0.1%
659	BSA). After washing, the Spike-ACE2 interaction was detected using
660	50 $\mu L$ SA-PE (Thermo Scientific, USA) (2 $\mu g/mL)$ for 30 minutes at
661	room temperature. Finally, after washing with PBST-B twice, the beads
662	were resuspended in a 200 $\mu L$ PBST-B solution. The fluorescent signal
663	was then detected at 200 beads/region using the EasyCell flow
664	cytometry (Wellgrow Technology Co., Ltd.) with excitation wavelengths
665	of 532 nm and 635 nm.
666	
667	Detection of monoclonal/polyclonal NAbs using the SARS-CoV-2
667 668	Detection of monoclonal/polyclonal NAbs using the SARS-CoV-2 bNAb assay
668	bNAb assay
668 669	bNAb assay To detect monoclonal/polyclonal NAbs, a 50 µL mixed solution
668 669 670	<b>bNAb assay</b> To detect monoclonal/polyclonal NAbs, a 50 μL mixed solution containing 7 different SARS-CoV-2 Spike trimer protein-coupled beads
668 669 670 671	bNAb assay To detect monoclonal/polyclonal NAbs, a 50 μL mixed solution containing 7 different SARS-CoV-2 Spike trimer protein-coupled beads (2500 beads per type) (Table S4) was added to each well of a 96-well

675	added to individual wells of a 96-well plate. After incubation for 2 h at
676	room temperature on a shaker, the beads were washed with PBST-B
677	three times, then the beads were incubated with 50 $\mu L$ biotinylated
678	ACE2 (0.5 $\mu$ g/mL) for 1 hour at room temperature. After washing, the
679	binding of ACE2 to Spike trimer proteins were detected using 50 $\mu\text{L}$
680	SA-PE (2 $\mu$ g/mL) for 30 minutes at room temperature. Finally, after
681	washing with PBST-B twice, the beads were resuspended in a 200 $\mu\text{L}$
682	PBST-B solution. The fluorescent signal was then detected at 200
683	beads/region using the EasyCell flow cytometry (Wellgrow Technology
684	Co., Ltd.) with excitation wavelengths of 532 nm and 635 nm.

685

#### 686 **Detection of Serum NAbs using SARS-CoV-2 bNAb assay.**

First, a 50 µL mixed solution containing 12 different SARS-CoV-2 Spike 687 688 trimer protein-coupled beads (2500 beads per type) (Table S2) was 689 added to each well of a 96-well plate, followed by 50 µL of the serum 690 samples which were diluted to 1:20 with PBST-B. After incubation for 2 h at room temperature on a shaker, the beads were washed with 691 692 PBST-B three times. Then the beads were incubated with 50 µL 693 biotinylated ACE2 (0.5 µg/mL) for 1 hour at room temperature. After washing, the binding of ACE2 to Spike trimer proteins were detected 694 695 using 50 µL SA-PE (2 µg/mL) and incubated the mixture for 30 minutes 696 at room temperature. Finally, after washing with PBST-B twice, the

beads were resuspended in a 200 µL PBST-B solution. The fluorescent
signal was then detected at 200 beads/region using the EasyCell flow
cytometry (Wellgrow Technology Co., Ltd.) with excitation wavelengths
of 532 nm and 635 nm.

701

# 702 Detection of Serum NAbs using the anti-Spike RBD IgG antibodies

#### 703 obtained by the ELISA.

The assay was conducted as described previously<sup>17</sup>. A capture 704 705 sandwich ELISA detection kit (PROPRIUM, Hangzhou, China) was 706 used to detect SARS-CoV-2 antibodies against the Spike protein RBD. 707 The SARS-CoV-2 Spike RBD protein was pre-coated onto the solid 708 phase, allowing it to form an antigen-antibody complex with IgG anti-RBD antibodies from 100 µL of diluted serum samples (1:30 709 710 dilution ratio) or standards. After washing, HRP-conjugated anti-human 711 IgG was added to form an antigen-antibody-HRP complex. The 712 substrate solution TMB was then introduced, and the resulting color 713 intensity was proportional to the level of SARS-CoV-2-neutralizing 714 antibodies. The optical density (OD) at 450 nm was measured, and a 715 threshold of 10 BAU/ml was used to determine sero-positive and 716 negative samples for anti-Spike RBD IgG.

717

# 718 Detection of Serum NAbs using cPass<sup>™</sup> sVNT Kit.

719 The assay was conducted as described previously<sup>17</sup>. Using competitive 720 ELISA, the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) 721 assay (Genscript, Nanjing, China) identified neutralizing antibodies 722 present in the bloodstream that obstruct the interaction between the 723 viral Spike glycoprotein receptor-binding domain (RBD) and human 724 ACE2. Following the manufacturer's instructions, diluted serum 725 samples (1:10 dilution ratio) and controls were pre-incubated at 37 for 726 15 minutes to allow binding of neutralizing antibodies (NAb) and 727 HRP-RBD (antigen derived from SARS-CoV-2 variant D614G), using a 1:1 volume ratio. Subsequently, the mixture was transferred to a 728 729 capture plate, pre-coated with hACE2 protein, where NAb-unbound 730 HRP-RBD was captured on the plate, while NAb-bound HRP-RBD 731 remained in the supernatant and was washed away. Next, 100 µL of 732 TMB and 50  $\mu$ L of stop solution were added, and the plate was read at 733 450 nm. The sample's absorbance was inversely correlated with the 734 titers of anti-SARS-CoV-2-neutralizing antibodies. To ensure result 735 validity, the OD450 values of positive controls (> 1.0) and negative 736 controls (< 0.3) had to fall within specific ranges. An inhibition rate of  $\geq$ 737 30% was considered positive for SARS-CoV-2-neutralizing antibody 738 determination. The inhibition rate was calculated as follows: 739 Inhibition  $\Box = \Box (1 - OD \text{ value of sample/OD value of negative})$ control)  $\Box \times \Box 100\%$ . 740

741

#### 742 **Pseudovirus-based neutralization assay.**

743 The SARS-CoV-2 pseudovirus was prepared using the VSV-ΔG system in which the glycoprotein (G) gene was replaced with the firefly 744 luciferase (Fluc) reporter gene <sup>33,34</sup>. The S protein was overexpressed 745 746 and displayed on the VSV pseudovirus. Following S-ACE2 interaction, 747 the pseudovirus entered the host cell where the Fluc gene was 748 transcribed and translated. The addition of luciferase substrate 749 resulted in luminescence where the amount of luminescence is 750 proportional to the level of pseudoviral entry. The preparation process 751 of SARS-CoV-2 pseudovirus begins with the cloning of the S gene 752 encoding the S protein of the virus. Subsequently, this gene is inserted 753 into a modified VSV backbone, replacing the original G gene. The 754 resulting construct, containing the S protein gene in lieu of the G gene 755 and complemented by the Fluc reporter gene, forms the foundation of 756 the pseudovirus. The pseudovirus equipped with the S protein can 757 interact with the ACE2 receptor on the surface of host cells, thereby 758 facilitating the entry of the pseudovirus into the cells. Once inside the 759 cells, the Fluc gene will be transcribed and translated to produce 760 luciferase.

The assay was conducted following previously described methods<sup>20,35</sup>. Huh7 cells were seeded at a concentration of  $2 \times 10^4$ 

763	cells per well in 96-well plates and incubated until reaching 90-100%
764	confluency, typically around 24 hours. Serum samples, subjected to
765	serial 3-fold dilutions commencing at 1:10, were then incubated with
766	650 TCID50 of the pseudovirus for a precisely controlled duration of 1
767	hour at 37 °C. Dulbecco's modified eagle medium (DMEM) served as
768	the negative control. As a crucial negative control, Dulbecco's Modified
769	Eagle Medium (DMEM) was employed. Following the incubation period,
770	the supernatant was carefully aspirated, making way for the addition of
771	luciferase substrate to each well. A subsequent 2-minute incubation in
772	darkness at room temperature facilitated optimal enzymatic reactions.
773	Luciferase activity, indicative of neutralizing antibody presence, was
774	quantified using the GloMax® 9633 Microplate Luminometer (Promega,
775	Madison, USA).

776

#### 777 Live virus based neutralization assay.

The assay was conducted as described previously<sup>35</sup>. To assess the 778 SARS-CoV-2-specific NAb titer in serum, we employed a cytopathic 779 effect (CPE)-based 780 microneutralization assay, utilizing the SARS-CoV-2 virus strain BetaCoV/Beijing/IME-BJ01/2020 (Accession 781 No. GWHACAX01000000) and Vero cells (ATCC, CCL81). Serum 782 samples underwent heat inactivation for 30 minutes at 56 °C and were 783 subsequently two-fold serially diluted (ranging from 1:4 to 1:2048) 784

using Dulbecco's Modified Eagle Medium (DMEM) from Thermo Fisher
Scientific. These dilutions were then mixed with an equivalent volume
of the virus solution to achieve a 50% tissue culture infectious dose
(TCID50) of 100 in each well.


789 The serum-virus mixtures were incubated for 1 hour at 37 °C to allow for sufficient neutralization reactions to occur. Following 790 791 incubation, the mixtures were gently added to 96-well plates containing 792 semi-confluent Vero cells with a density exceeding 80%. The plates 793 were then incubated for a further 3 days at 37 °C to allow for the 794 development of cytopathic effects (CPEs) on the Vero cells. Using an 795 inverted microscope, the CPEs on the Vero cells were carefully 796 observed and recorded. The neutralizing titer was determined as the 797 reciprocal of the highest sample dilution that successfully protected at 798 least 50% of the cells from CPE. In cases where no neutralization reaction was observable even at the initial serum dilution of 1:4, an 799 800 arbitrary titer of 2 (half of the limit of quantification) was assigned.

801


#### 802 Data analysis


To compare the inhibition rate (%) of serum NAbs against the D614G variant and other SARS-CoV-2 variants, the raw inhibition rates of different variants were first normalized using minimum-maximum normalization. Statistical analyses were performed using Student's


807	<i>t</i> -test, with a p-value $\leq$ 0.01 considered as statistically significant.
808	Correlations between the SARS-CoV-2 bNAb, ELISA-based serology
809	test, and the cPass sVNT test were determined using Pearson
810	correlation coefficients. Positive and negative percent agreement (PPA,
811	NPA) were performed using the positive and negative judgment results
812	from ELISA-based IgG serology and cPass sVNT tests. Ideal cutoffs
813	for the SARS-CoV-2 bNAb method that maximized PPA and NPA were
814	calculated using the Youden Index, which was implemented in the R
815	package pROC (v 1.18.2) $^{36}$ . All data analyses were carried out in R
816	(v4.2.3) under the R studio (v 19.1.3) environment.



LOD [µg/mL]	D614G	Alpha	Beta	Delta	Карра	Omicron BA.1	Average
Luminex	0.19	0.12	0.16	0.23	0.14	0.12	0.16
Wellgrow	0.006	0.003	0.005	0.003	0.007	0.008	0.005
Fold change [L/W] (×)	31.67	40	32	76.67	20	15	35.89±57.80 [-21.91~93.69]








В

D	D614G	Alpha	Beta	Delta	Карра	Omicron BA.1
#26	0.4739	0.511	1.021	0.5504	0.468	3.429
#20	1.365	1.524	1.266	1.343	1.324	> 10
Antibody 55# 55	0.8505	0.9199	0.8998	0.8429	0.9445	> 10
Anti #22	> 10	> 10	> 10	> 10	> 10	> 10
#23	> 10	> 10	> 10	> 10	> 10	> 10
#73	> 10	> 10	> 10	> 10	> 10	> 10

0

5



Vaccine type | | Inactivated | Recombinant